T1	Treatment 73 101	NMDA antagonist AR-R15896AR.
T2	Treatment 189 239	N-Methyl-D-Aspartate (NMDA) antagonist AR-R15896AR
T3	Treatment 569 587	placebo-controlled
T4	Treatment 825 870	Two loading doses of 3.5 mg/kg of AR-R15896AR
T5	Treatment 1540 1551	AR-R15896AR
T6	Treatment 1569 1576	placebo
T7	Treatment 1641 1652	AR-R15896AR
T8	Treatment 1677 1684	placebo
T9	Treatment 1798 1809	AR-R15896AR
T10	Treatment 1883 1895	AR-R15896AR:
T11	Treatment 2289 2300	AR-R15896AR
T12	Treatment 2408 2419	AR-R15896AR
T13	Treatment 2551 2558	placebo
